Ownership and insider activity for ORIC Pharmaceuticals, Inc. (ORIC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy.
Price
| Price | $12.54 |
| Market Cap | $1.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-26 | Piscitelli Dominic | M-Exempt | 25,000 | $150K |
| 2026-08-26 | Piscitelli Dominic | M-Exempt | 52,000 | $227K |
| 2026-08-26 | Piscitelli Dominic | M-Exempt | 25,000 | $150K |
| 2026-08-26 | Piscitelli Dominic | M-Exempt | 52,000 | $227K |
| 2026-08-26 | Piscitelli Dominic | S-Sale | 77,000 | $1.1M |
| 2026-07-24 | Heyman Richard A. | S-Sale | 6,100 | $73K |
| 2026-07-24 | Heyman Richard A. | M-Exempt | 3,500 | $6K |
| 2026-07-24 | Heyman Richard A. | S-Sale | 7,000 | $84K |
| 2026-07-24 | Heyman Richard A. | M-Exempt | 3,500 | $6K |
| 2026-07-06 | Heyman Richard A. | S-Sale | 300 | $4K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.8M | $42.6M | $89.2M | $78.4M | $226.0M | $66.8M | $23.4M | $59.4M | $45.7M |
| Short-term Investments | 0 | 0 | 0 | $215.2M | $11.0M | $139.4M | $184.8M | $196.6M | $235.8M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $26.6M | $43.7M | $90.0M | $296.7M | $240.5M | $210.5M | $212.6M | $262.2M | $288.5M |
| Property, Plant & Equipment | $2.9M | $2.5M | $2.2M | $2.0M | $2.4M | $14.3M | $12.0M | $2.9M | $9.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $30.0M | $46.7M | $94.1M | $299.0M | $298.6M | $250.4M | $254.7M | $274.1M | $411.0M |
| Accounts Payable | $940000 | $446000 | $152000 | $757000 | $1.9M | $1.3M | $944000 | $1.5M | $3.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $2.7M | $2.8M | 0 | $3.3M |
| Total Current Liabilities | $2.6M | $2.6M | $5.4M | $9.0M | $15.2M | $15.4M | $20.5M | $24.8M | $20.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.1M |
| Total Liabilities | $4.3M | $111.2M | $6.1M | $9.2M | $25.7M | $28.0M | $30.6M | $31.0M | $26.6M |
| Retained Earnings | -$44.4M | -$65.8M | -$92.7M | -$166.4M | -$245.1M | -$334.2M | -$434.9M | -$562.8M | -$692.2M |
| Total Equity | $25.7M | -$64.4M | $88.0M | $289.8M | $273.0M | $222.4M | $224.1M | $243.1M | $384.4M |
| Total Debt | 0 | 0 | 0 | 0 | $1.9M | $12.1M | $10.2M | $3.2M | $11.6M |
| Net Debt | -$25.8M | -$42.6M | -$89.2M | -$293.6M | -$235.1M | -$194.2M | -$198.0M | -$252.8M | -$269.9M |
| Working Capital | $24.0M | $41.1M | $84.6M | $287.7M | $225.4M | $195.1M | $192.1M | $237.4M | $268.0M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 13.19 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 13.45 |
Profitability
| Return on Equity | -35.35% |
| Return on Invested Capital | -40.32% |
| Return on Assets | -34.68% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AMLX · ATAI · ELVN · INBX · NKTR · PGEN · RLAY
Explore sector: Healthcare · Biotechnology
More sections of ORIC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks